Calyx Spins Out of Parexel
Calyx, a provider of Medical Imaging, eClinical, and Regulatory solutions and services to solve complex challenges in clinical research, has launched as an independent company following the strategic separation of the Parexel Informatics business from Parexel International.
“Today our industry needs to move at a 21st century pace and Calyx, as an independent company, is focused on enabling global biopharmaceutical customers and clinical research organizations (CROs) to leverage technology solutions and services in the pursuit of cures,” said Gavin Nichols, Chief Executive Officer at Calyx.
Calyx will remain privately held by the same ownership group that has owned and invested in Parexel since 2017.
Learn more,
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025